A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; OR-502 (Primary)
Indications Carcinoma; Malignant melanoma; Ovarian cancer; Sarcoma; Skin cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors OncoResponse

07 Nov 2024 Results presented in the OncoResponse media release.
04 Nov 2024 According to an OncoResponse media release, Phase 1 results from this study will be presented as a late-breaker poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), taking place in Houston, Texas, November 8-10, 2024.
29 Nov 2023 According to an OncoResponse media release, the company has dosed first patient in this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com